Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34
Rhea-AI Filing Summary
Telomir Pharmaceuticals director Whalen Matthew Pratt received a grant of 50,000 Non-Qualified Stock Options on April 16, 2026. The options have an exercise price of $1.3400 per share, expire on April 16, 2036, were granted under the 2023 Omnibus Incentive Plan, vested immediately, and leave him holding 50,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Whalen Matthew Pratt
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Options (right to buy) — 50,000 shares (Direct)
Footnotes (2)
- F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
- F2. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.
Key Figures
Options granted: 50000.0000 shares
Exercise price: $1.3400 per share
Expiration date: 2036-04-16
+3 more
6 metrics
Options granted
50000.0000 shares
Non-Qualified Stock Options granted on April 16, 2026
Exercise price
$1.3400 per share
Exercise price of the granted stock options
Expiration date
2036-04-16
Expiration date of the Non-Qualified Stock Options
Underlying shares
50000.0000 shares
Common stock underlying the granted options
Post-grant derivative holdings
50000.0000 options
Total derivative securities held directly after the grant
Grant date
2026-04-16
Date the stock options were issued and vested
Key Terms
Non-Qualified Stock Options, exercise price, 2023 Omnibus Incentive Plan, vested
4 terms
Non-Qualified Stock Options financial
"Security title reported as Non-Qualified Stock Options (right to buy)"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise price financial
"The exercise price of the stock options issued to the Reporting Person is equal"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2023 Omnibus Incentive Plan financial
"pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended"
vested financial
"All of the options vested immediately upon issuance."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Telomir Pharmaceuticals (TELO) report for Whalen Matthew Pratt?
Telomir Pharmaceuticals (TELO) granted director Whalen Matthew Pratt 50,000 Non-Qualified Stock Options on April 16, 2026. The options relate to 50,000 shares of common stock, were awarded as a grant under the 2023 Omnibus Incentive Plan, and vested immediately upon issuance.
What is the exercise price of the new TELO options granted to Whalen Matthew Pratt?
The options granted to Whalen Matthew Pratt carry an exercise price of $1.3400 per share. Footnote disclosure states this price equals the closing price of Telomir Pharmaceuticals common stock on April 16, 2026, the date the options were issued under the company incentive plan.
When do Whalen Matthew Pratt’s Telomir (TELO) stock options expire?
The Non-Qualified Stock Options granted to Whalen Matthew Pratt expire on April 16, 2036. This gives him a 10-year period from the grant date to exercise the options to purchase Telomir Pharmaceuticals common stock at the specified exercise price.
How quickly did the Telomir (TELO) options granted to Whalen Matthew Pratt vest?
All of the options granted to Whalen Matthew Pratt vested immediately upon issuance on April 16, 2026. There is no multi-year vesting schedule; he obtained full vesting rights to the 50,000 underlying common shares as soon as the options were granted.
How many Telomir (TELO) derivative securities does Whalen Matthew Pratt hold after this grant?
Following this award, Whalen Matthew Pratt holds 50,000 derivative securities directly, represented by the Non-Qualified Stock Options reported. The post-transaction holdings figure matches the full grant size, indicating all 50,000 options are now part of his reported beneficial holdings.
Was the Telomir (TELO) options grant to Whalen Matthew Pratt made under a Rule 10b5-1 plan?
The transaction is not identified as being under a Rule 10b5-1 trading plan. The related disclosure does not indicate that a pre-arranged trading plan governed this options grant, distinguishing it from transactions executed pursuant to such plans.